XBP1 and Miyoshi myopathy: Importantly, we also identified GAL-3, the ligand for LAG3, to be robustly expressed on CD138+ MM cells, and confirmed that anti-GAL-3 treatment can similarly augment immune responses against MM cells in patient BM, as well as XBP1/CD138/CS1 antigen-specific CTL.